BNP Paribas Financial Markets Acquires 6,764 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

BNP Paribas Financial Markets boosted its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 130.9% during the third quarter, Holdings Channel reports. The firm owned 11,930 shares of the company’s stock after acquiring an additional 6,764 shares during the quarter. BNP Paribas Financial Markets’ holdings in Trevi Therapeutics were worth $40,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Logos Global Management LP increased its stake in shares of Trevi Therapeutics by 27.3% during the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock valued at $8,344,000 after buying an additional 600,000 shares during the period. Bank of New York Mellon Corp lifted its stake in Trevi Therapeutics by 38.8% in the second quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock worth $532,000 after acquiring an additional 49,884 shares during the period. Ally Bridge Group NY LLC bought a new stake in Trevi Therapeutics in the second quarter valued at $4,395,000. American Century Companies Inc. increased its position in Trevi Therapeutics by 17.1% during the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after purchasing an additional 7,902 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in Trevi Therapeutics by 87.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after purchasing an additional 11,450 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on TRVI shares. B. Riley reaffirmed a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a research note on Monday, October 7th. Leerink Partners assumed coverage on Trevi Therapeutics in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective on the stock. HC Wainwright upped their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a report on Thursday, December 12th. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $9.31.

Trevi Therapeutics Price Performance

Shares of TRVI opened at $4.15 on Friday. The stock has a market cap of $318.99 million, a P/E ratio of -9.43 and a beta of 0.96. The business’s 50 day moving average price is $3.09 and its 200-day moving average price is $2.97. Trevi Therapeutics, Inc. has a 52 week low of $1.26 and a 52 week high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the firm posted ($0.08) earnings per share. On average, equities analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.